Journal article
Personalized medicine for cardiovascular diseases: how next generation epigenetic technologies can contribute?
Epigenomics, Vol.17(10), pp.675-680
07/03/2025
DOI: 10.1080/17501911.2025.2518917
PMCID: PMC12233864
PMID: 40515537
Abstract
Advances in DNA methylation and artificial intelligence have led to new methods for assessing risk and diagnosing coronary heart disease (CHD), the leading cause of death. However, whether these technologies can also be harnessed to generate new pharmacotherapeutic agents or monitor the effectiveness of new or existing CHD therapies is unknown. In this perspective, we review the development of cardiac assessment technologies and the challenges that these older approaches attempted to address. We next describe Precision Epigenetic methods and describe their strengths and limitations, as well as the conceptual framework through which these tools operate. Finally, we discuss their potential application to the development and evaluation of new therapies for CHD and how Precision Epigenetic tools compare to existing testing modalities for CHD. We conclude that the future is bright for the use of Precision Epigenetic methods in cardiovascular medicine and suggest that their routine use could lead to faster, less expensive and more effective healthcare.Advances in DNA methylation and artificial intelligence have led to new methods for assessing risk and diagnosing coronary heart disease (CHD), the leading cause of death. However, whether these technologies can also be harnessed to generate new pharmacotherapeutic agents or monitor the effectiveness of new or existing CHD therapies is unknown. In this perspective, we review the development of cardiac assessment technologies and the challenges that these older approaches attempted to address. We next describe Precision Epigenetic methods and describe their strengths and limitations, as well as the conceptual framework through which these tools operate. Finally, we discuss their potential application to the development and evaluation of new therapies for CHD and how Precision Epigenetic tools compare to existing testing modalities for CHD. We conclude that the future is bright for the use of Precision Epigenetic methods in cardiovascular medicine and suggest that their routine use could lead to faster, less expensive and more effective healthcare.
Details
- Title: Subtitle
- Personalized medicine for cardiovascular diseases: how next generation epigenetic technologies can contribute?
- Creators
- Meeshanthini DoganRobert Philibert
- Resource Type
- Journal article
- Publication Details
- Epigenomics, Vol.17(10), pp.675-680
- DOI
- 10.1080/17501911.2025.2518917
- PMID
- 40515537
- PMCID
- PMC12233864
- NLM abbreviation
- Epigenomics
- ISSN
- 1750-192X
- eISSN
- 1750-192X
- Publisher
- TAYLOR & FRANCIS LTD
- Grant note
- Cardio Diagnostics Inc
The effort preparing this manuscript was funded by Cardio Diagnostics Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- Language
- English
- Electronic publication date
- 06/14/2025
- Date published
- 07/03/2025
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984829887502771
Metrics
1 Record Views